Skip to main content

Table 2 Unadjusted SVR rates among patients stratified by treatment choice and baseline HCV characteristics

From: Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry

  Total
N = 309
TPV/PR
N = 215
BOC/PR
N = 94
  n/N SVR12 95% CI n/N SVR12 95% CI n/N SVR12 95% CI
Overall 215/309 69.6 64.5–74.7 158/215 73.5 67.6–79.4 57/94 60.6 50.7–70.5
Absence of cirrhosis 158/212 74.5 68.6–80.4 113/143 79 72.3–85.7 45/69 65.2 54–76.4
Presence of cirrhosis 48/79 60.8 47.8–69.2 36/55 65.5 52.9–78.1 12/24 50 30–70
Treatment naïve 153/217 70.5 64.4–76.6 109/146 74.7 67.6–81.8 44/71 56.5 36.2–76.4
Treatment experienced 61/89 68.5 58.8–78.2 48/66 72.7 62–83.4 13/23 62 50.7–73.3
Genotype 1a 115/172 66.9 59.9–73.9 84/119 70.6 62.4–78.8 31/53 58.5 45.2–71.8
Genotype 1b 64/86 74.4 65.2–83.6 46/55 83.6 78.8–93.4 18/31 58.1 40.7–70.5
Genotype 1 (no subtype) 35/49 71.4 58.7–84.1 27/39 69.2 54.7–83.7 8/10 80 55.2–104.8